Literature DB >> 26935332

Knockout of fractalkine receptor Cx3cr1 does not alter disease or microglial activation in prion-infected mice.

James F Striebel1, Brent Race1, James A Carroll1, Katie Phillips1, Bruce Chesebro1.   

Abstract

Microglial activation is a hallmark of the neuroimmunological response to Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis and prion disease. The CX3C chemokine axis consists of fractalkine (CX3CL1) and its receptor (CX3CR1); these are expressed by neurons and microglia respectively, and are known to modulate microglial activation. In prion-infected mice, both Cx3cr1 and Cx3cl1 are altered, suggesting a role in disease. To investigate the influence of CX3C axis signalling on prion disease, we infected Cx3cr1 knockout (Cx3cr1-KO) and control mice with scrapie strains 22L and RML. Deletion of Cx3cr1 had no effect on development of clinical signs or disease incubation period. In addition, comparison of brain tissue from Cx3cr1-KO and control mice revealed no significant differences in cytokine levels, spongiosis, deposition of disease-associated prion protein or microglial activation. Thus, microglial activation during prion infection did not require CX3C axis signalling.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26935332      PMCID: PMC5042093          DOI: 10.1099/jgv.0.000442

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  28 in total

1.  CX3CR1 regulates intestinal macrophage homeostasis, bacterial translocation, and colitogenic Th17 responses in mice.

Authors:  Oscar Medina-Contreras; Duke Geem; Oskar Laur; Ifor R Williams; Sergio A Lira; Asma Nusrat; Charles A Parkos; Timothy L Denning
Journal:  J Clin Invest       Date:  2011-12       Impact factor: 14.808

2.  Crucial involvement of the CX3CR1-CX3CL1 axis in dextran sulfate sodium-mediated acute colitis in mice.

Authors:  Feodora I Kostadinova; Tomohisa Baba; Yuko Ishida; Toshikazu Kondo; Boryana K Popivanova; Naofumi Mukaida
Journal:  J Leukoc Biol       Date:  2010-03-24       Impact factor: 4.962

Review 3.  Neuronal 'On' and 'Off' signals control microglia.

Authors:  Knut Biber; Harald Neumann; Kazuhide Inoue; Hendrikus W G M Boddeke
Journal:  Trends Neurosci       Date:  2007-10-24       Impact factor: 13.837

4.  Analysis of fractalkine receptor CX(3)CR1 function by targeted deletion and green fluorescent protein reporter gene insertion.

Authors:  S Jung; J Aliberti; P Graemmel; M J Sunshine; G W Kreutzberg; A Sher; D R Littman
Journal:  Mol Cell Biol       Date:  2000-06       Impact factor: 4.272

5.  Early cytokine elevation, PrPres deposition, and gliosis in mouse scrapie: no effect on disease by deletion of cytokine genes IL-12p40 and IL-12p35.

Authors:  Déborah Tribouillard-Tanvier; Brent Race; James F Striebel; James A Carroll; Katie Phillips; Bruce Chesebro
Journal:  J Virol       Date:  2012-07-11       Impact factor: 5.103

Review 6.  What is microglia neurotoxicity (Not)?

Authors:  Knut Biber; Trevor Owens; Erik Boddeke
Journal:  Glia       Date:  2014-03-03       Impact factor: 7.452

Review 7.  The immunobiology of prion diseases.

Authors:  Adriano Aguzzi; Mario Nuvolone; Caihong Zhu
Journal:  Nat Rev Immunol       Date:  2013-11-05       Impact factor: 53.106

8.  Distinct patterns of spread of prion infection in brains of mice expressing anchorless or anchored forms of prion protein.

Authors:  Alejandra Rangel; Brent Race; Katie Phillips; James Striebel; Nancy Kurtz; Bruce Chesebro
Journal:  Acta Neuropathol Commun       Date:  2014-01-21       Impact factor: 7.801

Review 9.  Fractalkine regulation of microglial physiology and consequences on the brain and behavior.

Authors:  Rosa Chiara Paolicelli; Kanchan Bisht; Marie-Ève Tremblay
Journal:  Front Cell Neurosci       Date:  2014-05-13       Impact factor: 5.505

10.  Microglial Cx3cr1 knockout reduces prion disease incubation time in mice.

Authors:  Julia Grizenkova; Shaheen Akhtar; Sebastian Brandner; John Collinge; Sarah E Lloyd
Journal:  BMC Neurosci       Date:  2014-03-21       Impact factor: 3.288

View more
  9 in total

Review 1.  Microglia in prion diseases.

Authors:  Adriano Aguzzi; Caihong Zhu
Journal:  J Clin Invest       Date:  2017-07-17       Impact factor: 14.808

2.  Statins are ineffective at reducing neuroinflammation or prolonging survival in scrapie-infected mice.

Authors:  James A Carroll; Brent Race; Katie Phillips; James F Striebel; Bruce Chesebro
Journal:  J Gen Virol       Date:  2017-07-31       Impact factor: 3.891

3.  Loss of Fractalkine Signaling Exacerbates Axon Transport Dysfunction in a Chronic Model of Glaucoma.

Authors:  Kevin T Breen; Sarah R Anderson; Michael R Steele; David J Calkins; Alejandra Bosco; Monica L Vetter
Journal:  Front Neurosci       Date:  2016-11-24       Impact factor: 4.677

4.  Inflammatory response of microglia to prions is controlled by sialylation of PrPSc.

Authors:  Saurabh Srivastava; Elizaveta Katorcha; Natallia Makarava; James P Barrett; David J Loane; Ilia V Baskakov
Journal:  Sci Rep       Date:  2018-07-27       Impact factor: 4.379

Review 5.  Neuroinflammation, Microglia, and Cell-Association during Prion Disease.

Authors:  James A Carroll; Bruce Chesebro
Journal:  Viruses       Date:  2019-01-15       Impact factor: 5.048

Review 6.  Neuroinflammation in Prion Disease.

Authors:  Bei Li; Meiling Chen; Caihong Zhu
Journal:  Int J Mol Sci       Date:  2021-02-23       Impact factor: 5.923

7.  Absence of Apolipoprotein E is associated with exacerbation of prion pathology and promotes microglial neurodegenerative phenotype.

Authors:  Joanna E Pankiewicz; Anita M Lizińczyk; Leor A Franco; Jenny R Diaz; Mitchell Martá-Ariza; Martin J Sadowski
Journal:  Acta Neuropathol Commun       Date:  2021-09-26       Impact factor: 7.578

Review 8.  Microglia in neurodegeneration.

Authors:  Suzanne Hickman; Saef Izzy; Pritha Sen; Liza Morsett; Joseph El Khoury
Journal:  Nat Neurosci       Date:  2018-09-26       Impact factor: 24.884

Review 9.  Microglia in Prion Diseases: Angels or Demons?

Authors:  Caterina Peggion; Roberto Stella; Paolo Lorenzon; Enzo Spisni; Alessandro Bertoli; Maria Lina Massimino
Journal:  Int J Mol Sci       Date:  2020-10-20       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.